Abstract | BACKGROUND AND OBJECTIVES: METHODS: RESULTS: We evaluated 123,200 MMRV and 584,987 MMR + V doses. Comparing MMRV with MMR + V, risks for the 7 main outcomes were not significantly different. Several outcomes had few or zero postvaccination events. Comparing risk versus comparison intervals, ITP risk was higher after MMRV (odds ratio [OR]: 11.3 [95% confidence interval (CI): 1.9 to 68.2]) and MMR + V (OR: 10 [95% CI: 4.5 to 22.5]) and ataxia risk was lower after both vaccines (MMRV OR: 0.8 [95% CI: 0.5 to 1]; MMR + V OR: 0.8 [95% CI: 0.7 to 0.9]). Compared with MMR + V, MMRV increased risk of seizure and fever 7 to 10 days after vaccination. CONCLUSIONS: This study did not identify any new safety concerns comparing MMRV with MMR + V or after either the MMRV or the MMR + V vaccine. This study provides reassurance that these outcomes are unlikely after either vaccine.
|
Authors | Nicola P Klein, Edwin Lewis, Bruce Fireman, Simon J Hambidge, Allison Naleway, Jennifer C Nelson, Edward A Belongia, W Katherine Yih, James D Nordin, Rulin C Hechter, Eric Weintraub, Roger Baxter |
Journal | Pediatrics
(Pediatrics)
Vol. 135
Issue 2
Pg. e321-9
(Feb 2015)
ISSN: 1098-4275 [Electronic] United States |
PMID | 25560438
(Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Copyright | Copyright © 2015 by the American Academy of Pediatrics. |
Chemical References |
- Biomarkers, Pharmacological
- Chickenpox Vaccine
- Measles-Mumps-Rubella Vaccine
- Vaccines, Combined
- measles, mumps, rubella, varicella vaccine
|
Topics |
- Biomarkers, Pharmacological
- Chickenpox Vaccine
(administration & dosage, adverse effects)
- Cohort Studies
- Female
- Humans
- Infant
- Male
- Measles-Mumps-Rubella Vaccine
(administration & dosage, adverse effects)
- Risk Assessment
- Seizures, Febrile
(chemically induced)
- United States
- Vaccines, Combined
(administration & dosage, adverse effects)
|